二肽基肽酶4作为活化成纤维细胞标志物及系统性硬化症纤维化治疗潜在靶点
该研究探讨二肽基肽酶4(DPP-4)在系统性硬化症(SSc)皮肤纤维化中的作用。研究发现SSc患者纤维化皮肤中DPP-4表达及阳性成纤维细胞数量增加,且呈TGFβ依赖方式;药物抑制或基因敲除DPP4可减轻小鼠模型纤维化。DPP-4抑制剂已用于糖尿病,可能对SSc纤维化治疗有直接转化意义。
要点
- SSc纤维化皮肤中DPP-4表达及阳性成纤维细胞增多,呈TGFβ依赖。
- DPP-4阳性成纤维细胞表达更高水平的肌成纤维细胞标志物和胶原。
- 药物抑制或基因敲除DPP4可减轻小鼠皮肤和肺纤维化并促进消退。
核心结论
- DPP-4标志一群活化成纤维细胞,并调控SSc患者纤维化皮肤中TGFβ诱导的成纤维细胞活化。
- 抑制DPP4在耐受剂量下发挥强效抗纤维化作用,因DPP-4抑制剂已临床用于糖尿病,对SSc纤维化治疗有直接转化意义。
研究设计与样本
- 分析SSc患者皮肤活检样本及真皮成纤维细胞中DPP-4表达(实时PCR、免疫荧光、Western blot)。
- 通过过表达、敲低及西格列汀和维格列汀药理抑制调控DPP4活性。
- 在人真皮成纤维细胞及不同SSc小鼠模型(每组n=6)中分析DPP4抑制效果。
主要发现
- SSc患者纤维化皮肤中DPP-4表达及DPP-4阳性成纤维细胞数量增加,呈TGFβ依赖方式。
- DPP-4阳性成纤维细胞表达更高水平的肌成纤维细胞标志物和胶原(均P<0.001 vs 健康对照)。
- 过表达DPP4促进成纤维细胞活化,而药理抑制或基因失活DPP4减少增殖、迁移、收缩蛋白表达及胶原释放(均P<0.001 vs 对照小鼠),干扰TGFβ诱导的ERK信号。
- DPP4敲除小鼠对博来霉素诱导的皮肤和肺纤维化敏感性降低(P<0.0001 vs 野生型对照)。
- DPP4抑制剂治疗促进博来霉素攻击小鼠和慢性移植物抗宿主病小鼠纤维化消退,并改善TSK1小鼠纤维化(均P<0.001 vs 未治疗对照),抗纤维化效应伴炎症减少。
临床怎么用
- DPP-4抑制剂(如西格列汀、维格列汀)已在糖尿病临床使用,可能为SSc纤维化治疗提供转化机会。
- DPP-4可作为活化成纤维细胞标志物,用于评估SSc纤维化活动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Expression of dipeptidylpeptidase 4 (DPP-4) identifies a dermal fibroblast lineage involved in scarring during wound healing. The role of DDP-4 in tissue fibrosis is, however, unknown. The aim of the present study was to evaluate DPP-4 as a potential target for the treatment of fibrosis in patients with systemic sclerosis (SSc). METHODS: Expression of DPP-4 in skin biopsy samples and dermal fibroblasts was analyzed by real-time polymerase chain reaction, immunofluorescence, and Western blot analyses. The activity of DPP-4 was modulated by overexpression, knockdown, and pharmacologic inhibition of DPP4 using sitagliptin and vildagliptin. The effects of DPP4 inhibition were analyzed in human dermal fibroblasts and in different mouse models of SSc (each n = 6). RESULTS: The expression of DPP-4 and the number of DPP-4-positive fibroblasts were increased in the fibrotic skin of SSc patients, in a transforming growth factor β (TGFβ)-dependent manner. DPP-4-positive fibroblasts expressed higher levels of myofibroblast markers and collagen (each P < 0.001 versus healthy controls). Overexpression of DPP4 promoted fibroblast activation, whereas pharmacologic inhibition or genetic inactivation of DPP4 reduced the proliferation, migration, and expression of contractile proteins and release of collagen (each P < 0.001 versus control mice) by interfering with TGFβ-induced ERK signaling. DPP4-knockout mice were less sensitive to bleomycin-induced dermal and pulmonary fibrosis (P < 0.0001 versus wild-type controls). Treatment with DPP4 inhibitors promoted regression of fibrosis in mice that had received bleomycin challenge and mice with chronic graft-versus-host disease, and ameliorated fibrosis in TSK1 mice (each P < 0.001 versus untreated controls). These antifibrotic effects were associated with a reduction in inflammation. CONCLUSION: DPP-4 characterizes a population of activated fibroblasts and shows that DPP-4 regulates TGFβ-induced fibroblast activation in the fibrotic skin of SSc patients. Inhibition of DPP4 exerts potent antifibrotic effects when administered in well-tolerated doses. As DPP4 inhibitors are already in clinical use for diabetes, these results may have direct translational implications for the treatment of fibrosis in patients with SSc.
引用
- Soare A, Györfi HA, Matei AE, et al. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. Arthritis Rheumatol. 2020. PMID: 31350829. doi:10.1002/art.41058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。